Testing QLS5316 for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests a new experimental drug called QLS5316 for people with advanced solid tumors that have not responded to standard treatments. The drug works like a 'smart bomb'—it seeks out and delivers medicine directly to cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have a type of advanced solid tumor that has not gotten better with standard treatments, or for which no standard treatment exists.
- You should be in generally good health (able to care for yourself and out of bed more than half the day).
- If you have had certain prior treatments (like ADCs targeting topoisomerase I, EGFR, or c-MET), you cannot join this study.
- You cannot have untreated or active brain metastases, or a history of certain lung conditions like interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
This trial tests an investigational drug called QLS5308 for people with advanced solid tumors that have not responded to standard treatments. The study's goal is to find a safe dose and see how well it works.
This trial tests a new drug called QLS5132, alone or in combination, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.